All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Despite the existence of effective antituberculosis drugs, tuberculosis (TB) continues to be a major global health challenge with an estimated 9 million new active cases and 1.5 million TB deaths annually (just under 1 million). Moreover, control efforts to fight TB are threatened by the emergence of different forms of drug resistance \[[@pone.0135695.ref001],[@pone.0135695.ref002]\]. In Morocco, TB is a major public health problem with a relatively high incidence reaching 83 new cases for 100000 inhabitants \[[@pone.0135695.ref003]\]. TB affects especially young adults and therefore has a high impact on the socio-economic situation of the country. TB control remains a priority in Morocco, thus a better understanding of TB transmission could help to identify risk settings as well as to improve contact tracing.

Molecular typing of MTBC is a powerful adjunct to TB control e.g, to monitor the disease transmission, and to detect or confirm outbreaks. In the last decade, the optimized 15 to 24-locus MIRU-VNTR typing system has been proposed for international standardization \[[@pone.0135695.ref004]\]. This PCR-based system, optionally combined with spoligotyping \[[@pone.0135695.ref005]\], has been shown to provide a similar resolution power relative to the previous IS*6110* restriction fragment length polymorphism (RFLP) standard for the study of TB transmission in different Western European settings \[[@pone.0135695.ref006]--[@pone.0135695.ref008]\]. Moreover, MIRU-VNTR typing is also useful for studying at relatively high resolution the diversity and clonal expansion of particular strain or lineages \[[@pone.0135695.ref009]--[@pone.0135695.ref011]\].

Only a few studies have investigated MTBC genetic diversity in Morocco \[[@pone.0135695.ref012]--[@pone.0135695.ref017]\]. El Baghdadi et *al*.(1997) and Diraa et *al*.(2005), used IS*6110*-based Restriction Fragment Length Polymorphism (RFLP), whereas Tazi et *al*.(2004,2007), Lahlou et *al*.(2012) and Chaoui et *al*. (2014) used spoligotyping alone or in combination with a 12-locus MIRU-VNTR typing for molecular epidemiological analyses of Moroccan isolates \[[@pone.0135695.ref013],[@pone.0135695.ref015]--[@pone.0135695.ref017]\]. The purpose of the present study was therefore to assess standard 24-locus based MIRU-VNTR typing for the first time, on a panel of MTBC isolates collected from diverse geographical cities from Morocco. We tested 168 isolates by spoligotyping, then we evaluated the usefulness of this standardized 24-locus based MIRU-VNTR typing on a subset of 75 MTBC. The specific aims of this study were to evaluate the diversity of circulating MTBC strains at a higher resolution compared to most previous studies and to establish possible links between drug resistance profiles and molecular types.

Material and Methods {#sec006}
====================

Study population and setting {#sec007}
----------------------------

TB patients from eight regions of different ethnic groups of Morocco were included in the study. MTBC strains were collected within the framework of immuno-genetics study of the tuberculosis in the population over a period of 3 years; between January 2010 and December 2012. For this molecular epidemiological study, patients were recruited from 12 public health centers and 2 university hospitals. Pulmonary samples were collected from 10 Centers of TB Treatment and Respiratory Disease (CTRD) located in Marrakech, Tanger, Oujda, Fes, Meknes, Sidi Kacem, Sale, Temara, Casablanca and Rabat, whereas extrapulmonary samples (pleural fluid and gastric liquid) were collected from two university hospitals in Casablanca and Rabat. These cities are known to be hot spot areas of TB at National level.

### Patient isolates {#sec008}

A total of 471 clinical samples were recruited in this study corresponding to 167 patients, from which 155 (92.81%) had pulmonary TB (sputum, sputum induced by fibro-optic bronchoscopy, bronchial wash and bronchial aspirations), 11 (6.58%) patients had extrapulmonary TB (pleural fluid and gastric liquid) and 1 (0.59%) patient with both (pulmonary and extrapulmonary TB). Two patients were re-treatment cases, while the remaining 165 were new cases ([Table 1](#pone.0135695.t001){ref-type="table"}). All pulmonary patients had sputum microscopy positive according to their clinical manifestation; pulmonary and extrapulmonary TB cases were included by cluster sampling from 10 cities (Rabat, Temara, Sale, Casablanca, Marrakech, Sidi Kacem, Meknes, Fes, Oujda and Tanger). Sputum smear microscopy and culture for the collected samples were performed in regional laboratories, then the isolates were submitted to National Reference Laboratory of Tuberculosis (LNRT) at the National Institute of Hygiene in Rabat, for identification and drug susceptibility testing (DST) to first line drugs. Culture of pleural liquid (PL) samples was performed at LNRT.

10.1371/journal.pone.0135695.t001

###### Demographic and epidemiological data of the studied population from Morocco (n = 167)

![](pone.0135695.t001){#pone.0135695.t001g}

  Administrative regions        Isolation city   n(%)        Sex-ratio (M/F)                            Mean age (Ecartype) (Year)                 New cases n(%)   Previously treated cases n(%)
  ----------------------------- ---------------- ----------- ------------------------------------------ ------------------------------------------ ---------------- -------------------------------
  Grand Casablanca              Casa             5(2.98)     4/1                                        44.8(25.74)                                5(100)           0
  Fes-Boulmane                  Fes              16(9.53)    12/4                                       29.56(7.6)                                 16(100)          0
  Marrakech-Tansift- Al Haouz   Marrakech        34(20.23)   27/7                                       34.17(10.35)                               34(100)          0
  Region Oriental               Oujda            4(2.38)     2/2                                        39.25(3.20)                                4(100)           0
  Rabat-Sale-Zemmour-Zaêr       Rabat            66(39.52)   50/16                                      33.92(13.32)                               66(100)          0
  Sale                          16(9.52)         10/6        26.25(7.39)                                16(100)                                    0                
  Temara                        4(2.38)          100% M      41,5(26.73)                                4(100)                                     0                
  Gharb-Chrarda-BniHssen        Sidi Kacem       1(0.6)      [^d^](#t001fn002){ref-type="table-fn"}NA   [^d^](#t001fn002){ref-type="table-fn"}NA   1(100)           0
  Meknes-Tafilalt               Meknes           2(1.19)     100% F                                     23(4.24)                                   0                2(100)
  Tanger-Tetouan                Tanger           19(11.3)    14/5                                       32.68(9.51)                                19(100%)         0
  Total                         10               167         124/43                                     32.25(12.23)                               165              2

M: Male; F: Female

^d^NA: Not applicable since only one patient originated from this city.

Ethical approval statement was obtained (Reference number 1169) from ethics committee named "comité d'éthique de Médicine et de Pharmacie de Rabat"; participants provide their written informed consent and the ethics committee approves these consent procedures and the present study.

All TB patients were diagnosed according to the national guidelines in Morocco.

Strains isolation and drug susceptibility testing {#sec009}
-------------------------------------------------

The clinical samples were cultured on Lowenstein-Jensen (L/J) culture media and on Growth Indicator Tubes (MGIT) 960 culture tubes inoculated in Bactec System. The isolates (n = 168) were subjected to identification as MTBC using biochemical tests including production of Niacin (Strip Niacin \[Becton Dickinson, CA, USA\]), catalase activity and susceptibility testing of MTBC to P-Nitrobenzoic acid (PNB), Thiophene-2-carboxylic acid hydrazide (TCH) and paraaminosalicylic acid (PAS) \[[@pone.0135695.ref018]\]. First line drug susceptibility testing was performed using the 1% proportion method for isoniazid (INH), rifampicin (RMP), streptomycin (SM) and ethambutol (EMB) at the following concentrations: 0.2 mg/ml, 40 mg/ml, 4 mg/ml and 2 mg/ml respectively on L/J medium \[[@pone.0135695.ref019]\] and using BACTEC MGIT 960 SIRE kit \[Becton Dickinson, CA, USA\]. Results were categorized into three major groups, i.e. resistance to a single drug (mono resistance), to more than one drug but not INH and RMP (polyresistance), and resistance to at least both INH and RMP (MDR-TB, \[[@pone.0135695.ref018]\]). Epidemiological and demographic data such as age, sex, city of birth, address at the time of diagnosis, place of residence and clinical characteristics of the disease were prospectively collected using a questionnaire established within the study framework.

Molecular methods {#sec010}
-----------------

Genomic DNA was prepared from scarped colonies in 200 μl of 1xTE buffer (10mM Tris-HCl pH: 8.0, 1mM EDTA pH: 8.0) followed by heat inactivation at 85° for 30 min \[[@pone.0135695.ref020]\]. Spoligotyping was carried out for 168 isolates, using the commercially available membranes (Ocimum Biosolutions, Hyderabad, India) \[[@pone.0135695.ref005]\]. Standard 24-locus based MIRU-VNTR typing was performed for 75 isolates using the available commercial kit (Genoscreen, Lille, France) and 16 capillary ABI 3730 genetic analyzer (Applied Biosystems, CA, 78 USA) as described previously \[[@pone.0135695.ref004]\]. MIRU-VNTR alleles were determined by using Genemapper V-4.0 (Applied Biosystems, CA,79 USA) and data were compiled by using MIRU-VNTR Data Manager software (Genoscreen, Lille, France).

Molecular data analysis {#sec011}
-----------------------

Spoligotyping results were converted into octal codes and entered in SITVIT database \[[@pone.0135695.ref021]\] for analysis. Major spoligotypes families were assigned according to signatures provided in the database. Distinction between evolutionary, ancient, and modern lineages of tubercle bacilli was made as described \[[@pone.0135695.ref022]--[@pone.0135695.ref027]\]. MTBC genetic lineages were predicted using online tools available from MIRU-VNTR*plus* website ([www.miruvntrplus.org](http://www.miruvntrplus.org) \[[@pone.0135695.ref028]\]) according to the previously described strategy combining best-match and phylogenetic based analysis \[[@pone.0135695.ref029]\] and by using information in the SITVIT database (fr:8081/SITVIT ONLINE/indexjsp). Molecular clustering of the isolates was determined by constructing a dendogram based on spoligotyping and MIRU-VNTR data. A strain cluster was defined as two or more isolates sharing completely identical fingerprints based on both methods. Discriminatory power of a typing method (or a combination of methods) was calculated using the Hunter and Gaston Discriminatory Index (HGDI) \[[@pone.0135695.ref030]\]. Cases of isolates displaying double alleles in one locus suggestive of clonal microevolution \[[@pone.0135695.ref031]\], or in two or more VNTR loci suggestive of mixed genotypes, which could reflect either mixed infection or contamination \[[@pone.0135695.ref032]\] were retested.

Results {#sec012}
=======

Study Population {#sec013}
----------------

A total of 168 isolates were enrolled in this study, from 167 patients were selected from 10 cities located in 8 of 16 administrative regions of Morocco (51.79% from Rabat-Sale-Zemmour-Zaêr, 20.23% from Marrakech-Tansift-Al Haouz, 11.3% from Tanger-Tetouan, 9.53% from Fes-Boulmane, 2.98% from Grand Casablanca, 2.38% from Region Oriental, 1.19% from Meknes-Tafilalt and 0.6% from Gharb-Chrarda-BniHssen). These cities are known to be hot spot areas of TB. The demographic and epidemiological data summarized in [Table 1](#pone.0135695.t001){ref-type="table"} showed that the age of patients ranged from 18 to 81 years (mean 49.5 years). Gender information was available for all cases: males represented 74.25% of the cases, with a male to female sex-ratio of 2.9 (124/43). There was no correlation between localities (administrative regions) and age/sex-ratio of patients. Clinical status was available for all TB patients: 98.8% (165/167) were new cases and 1.19% (2/167) were previously treated. 92.81% (155/167) had pulmonary TB, while 6.58% (11/167) had extrapulmonary TB. One patient (0.59%) had both pulmonary and extrapulmonary TB ([Table 1](#pone.0135695.t001){ref-type="table"}).

Drug susceptibility {#sec014}
-------------------

The drug susceptibility testing (DST) data was available for all cases, and showed that 88.7% (149/168) of the strains were pansusceptible, while the remaining 11.3% (19/168) showed resistance to one or more drugs. Among the resistant strains, monoresistance to INH, SM and EMB was found in 6.0%, 0.6% and 0.6% of the tested strains respectively, as opposed to none for RMP. Of note, MDR isolates represented only 5 (3.0%) of 165 new TB cases included in the study. In contrast, the two remaining retreatment cases were MDR.

Spoligotyping data analysis {#sec015}
---------------------------

Analysis of the spoligotyping data was done by assigning shared international type (SIT) numbers and genotypic spoligotype family designations in comparison with SpolDB4 \[[@pone.0135695.ref021]\] and its updated SITVIT version \[[@pone.0135695.ref022]\] ([S1 Table](#pone.0135695.s001){ref-type="supplementary-material"}). The global sample containing 10/168 (6.0%) isolates that could not be assigned into well-determined designations in both, and as such were labeled as ''unknown". In contrast, the remaining, 158 isolates belonged to 39 classified SITs in the international SITVIT database. A total of 137/168 (81.54%) clinical isolates were clustered 18 clusters containing 2--50 isolates per cluster while 31 were unique (21 with an assigned SIT, and 10 unknown from SITVIT).

The major spoligotype families observed ranked as follows: Latin-American & Mediterranean or LAM, 81/168 (48.21%) with the following subfamily distribution: LAM3 n = 8; LAM5 n = 1; LAM6 n = 1; LAM9 n = 67; CAM alias Cameroon, n = 4; Haarlem, 40/168 (23.80%) with the following subfamily distribution H1 n = 11; H3 n = 29; T superfamily 26/168 (15.47%) with the following distribution: T1 n = 24; T2 n = 2; Beijing, 5/168 (2.97%); U clade, 4/168 (2.38%) and S clade, 2/168 (1.19%). No X lineage strains or EAI (East-African Indian) strains were found in the present investigation.

Regarding the frequencies of the major shared types, SIT42 (LAM9) strongly predominated in our setting with 49/168 (29.16%) of the isolates. It was followed by SIT53 (T spoligotype group) with 19/168 isolates (11.3%) and SIT50 (Haarlem) with 17/168 isolates (10.1%). These three predominant SITs were widespread in all Moroccan cities included in this study. Interestingly, 8 isolates, with a priori more unexpected spoligotypes, corresponding to SIT61 (CAM: n = 4), to SIT1070 (U: n = 3) and SIT443 (U: n = 1), were isolated either in the capital city's administrative region of Rabat-Sale-Zemmour-Zaer, or in the cosmopolite and touristic administrative regions of Marrakech-Tensift-Al Haouz and Fes-Boulmane ([Table 2](#pone.0135695.t002){ref-type="table"}). Likewise, we also found 5 isolates (2.97%) with a SIT1 (Beijing) spoligotype among cases from Marrakech-Tansift-Al Haouz, Rabat-Sale-Zemmour-Zaer and Grand Casablanca capital of touristic region.

10.1371/journal.pone.0135695.t002

###### Detailed Results obtained including demographic, drug-resistance and genotyping information on 5 Clusters and 69 unique patterns defined by identical spoligotyping and 24-loci MIRU from 75 *M*.*tuberculosis* strain isolated in Morocco.
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  ID    Year of Isolation   Sex   Age   City          site of Infection   Spoligotype Description                       Cluster(SIT/Clade)    MIRU24 profil               MLVA MtbC15-9   DST status           
  ----- ------------------- ----- ----- ------------- ------------------- --------------------------------------------- --------------------- --------------------------- --------------- ------------ --- --- -------
  83    2011                M     81    Casablanca    Extrapulmonary      ▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▪▪▪▪▪▪▪▪▪   NC(1/Beijing)         244233352644425173353723    100--32         r            s   s   r
  18    2011                M     26    Rabat         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▫▫▪▫▫▫▫▪▪▪▪▪▪▪   Cluster A(47/H1)      223235332332423153333732    322--31         s            s   s   s
  27    2011                M     43    Rabat         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▫▫▪▫▫▫▫▪▪▪▪▪▪▪   Cluster A(47/H1)      223235332432423153323732    1509--31        r            s   s   s
  32    2011                M     32    Fes           Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▫▫▪▫▫▫▫▪▪▪▪▪▪▪   Cluster A(47/H1)      223335332432423153334832    Unk-31          s            s   s   s
  77    2011                M     26    Sale          Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▫▫▪▫▫▫▫▪▪▪▪▪▪▪   Cluster A(47/H1)      223215372532423133334732    Unk-31          s            s   s   s
  11    2011                M     31    Rabat         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▪▫▫▫▫▪▪▪▪▪▪▪   Cluster B(50/H3)      223225321632423153333622    307--76         s            s   s   s
  17    2011                M     19    Rabat         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▪▫▫▫▫▪▪▪▪▪▪▪   Cluster B(50/H3)      233235322634425154233432    9927--415       s            s   s   s
  20    2012                M     28    Rabat         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▪▫▫▫▫▪▪▪▪▪▪▪   Cluster B(50/H3)      223232372532423123333232    Unk-31          r            s   s   r
  26    2011                M     20    Sale          Extrapulmonary      ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▪▫▫▫▫▪▪▪▪▪▪▪   Cluster B(50/H3)      134243352324126153332932    358--51         s            s   s   s
  44    2011                F     26    Fes           Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▪▫▫▫▫▪▪▪▪▪▪▪   Cluster B(50/H3)      223235321332425153333622    Unk-116         s            r   s   s
  63    2011                M     29    Rabat         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▪▫▫▫▫▪▪▪▪▪▪▪   Cluster B(50/H3)      233235322634425154233232    Unk-415         s            s   s   s
  65    2011                M     30    Temara        Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▪▫▫▫▫▪▪▪▪▪▪▪   Cluster B(50/H3)      123236372434425143333632    Unk-52          s            s   s   s
  70    2011                F     25    Rabat         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▪▫▫▫▫▪▪▪▪▪▪▪   Cluster B(50/H3)      123233332434425153333632    Unk-52          r            s   s   s
  79    2012                M     31    Rabat         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▪▫▫▫▫▪▪▪▪▪▪▪   Cluster B(50/H3)      233235322634425154233432    9927--415       s            s   s   s
  75    2011                M     37    Rabat         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▪▫▫▫▫▪▪▪▪▪▪▪   Cluster B(50/H3)      123236332434425153333632    2433--52        s            s   s   s
  21    2011                M     40    Fes           Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▪▪▪▪▪▪▪▫▪▫▫▫▫▪▪▪▪▪▪▪   Cluster C(741/H3)     223235332334425153333432    1808--15        s            s   s   s
  47    2011                M     26    Fes           Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▪▪▪▪▪▪▪▫▪▫▫▫▫▪▪▪▪▪▪▪   Cluster C(741/H3)     223215332434425153333732    1480--15        s            s   s   s
  55    2011                M     29    Rabat         Pulmonary           ▪▪▪▪▪▫▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▪▫▫▫▫▪▪▫▫▪▪▪   NC(1743/H3)           223235271332423153333722    Unk-76          s            s   s   s
  1     2010                F     43    Marrakech     Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster D(61/CAM)     223235372332425153333222    Unk-111         s            s   s   s
  49    2011                M     34    Fes           Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster D(61/CAM)     2242133316442251533311422   Unk-26          s            s   s   s
  3     2011                F     42    Oujda         Pulmonary           ▪▪▪▪▪▪▪▪▫▫▫▪▫▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▫▪▪▪   NC(33/LAM3)           224244322322225162342522    Unk-110         s            s   s   s
  69    2011                M     25    Rabat         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▫▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   NC(93/LAM5)           134264332224127143332832    Unk-68          s            s   s   s
  4     2011                M     42    Oujda         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     224213332322126133332022    Unk-259         s            s   s   s
  8     2011                M     53    Rabat         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     2420s0435232426123345132    Unk-62          s            s   s   s
  10    2011                M     34    Rabat         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     224244322324226173345522    369--62         s            s   s   s
  12    2011                M     24    Rabat         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     214222321324242173345222    Unk-Unk         s            s   s   s
  16    2011                M     31    Rabat         Extrapulmonary      ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     1342243352324126153332932   358--51         s            s   s   s
  24    2011                F     22    Casablkanca   Extrapulmonary      ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     134234372224126133332732    Unk-51          s            s   s   s
  29    2011                F     20    Fes           Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     1322643322241261633332632   Unk-51          r            s   s   s
  30    2010                M     34    Marrakech     Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     244244322324224143333522    Unk-82          r            s   s   s
  38    2011                M     36    Rabat         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     144254232224126153332732    Unk-51          s            s   s   s
  41    2011                M     40    Sale          Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     134254212224124153332732    Unk-83          s            s   s   s
  43    2011                F     19    Sale          Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     134244332224126153332532    239--51         s            s   s   s
  45    2011                F     26    Fes           Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     145244322324225182346522    Unk-72          s            s   s   **s**
  48    2011                M     20    Fes           Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     135274332224126153332732    Unk-51          s            s   s   s
  54    2011                F     42    Tanger        Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     2442234322424226133131722   300--53         s            s   s   s
  57    2011                M     42    Tanger        Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     134224332224126143332732    9823--51        s            s   s   s
  58    2011                M     24    Sale          Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     2432443323344251533431032   Unk-15          s            s   s   s
  59    2011                F     18    Sale          Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     2432443723324251533431032   Unk-111         s            s   s   s
  60    2011                F     21    Rabat         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     134224352222126133332332    Unk-1011        s            s   s   s
  62    2011                M     34    Sale          Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     224222322324226173344322    11247--62       r            s   s   s
  64    2011                M     81    Temara        Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     244214262324116143332122    Unk-92          s            s   s   S
  66    2011                M     20    Sale          Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     223122371532423123333622    Unk-76          s            s   s   S
  67    2011                M     32    Sale          Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     134284332224126153332632    Unk-51          s            s   s   S
  68    2012                M     20    Sale          Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     244244321322225182345122    Unk-Unk         s            s   s   S
  72    2011                M     21    Rabat         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     244244322324226163345522    11304--62       s            s   s   S
  94    2011                M     25    Rabat         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     242244322322226163345522    Unk-259         s            s   s   S
  166   2012                F     26    Meknes        Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     244244321322225172346522    10248-Unk       r            r   s   r
  168   2012                F     20    Meknes        Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     244244321322225172346522    10248-Unk       r            r   s   r
  169   2012                M     19    Sidi Kacem    Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     244244321322225172346522    10248-Unk       r            r   s   r
  170   2011                M     43    Marrakech     Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(42/LAM9     244214322232422463332622    220--82         s            s   s   s
  19    2011                M     37    Oujda         Pulmonary           ▪▪▪▪▫▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster E(822/LAM9)   224213371844225133333222    Unk-26          s            s   s   s
  37    2011                M     33    Rabat         Pulmonary           ▪▪▪▪▫▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster E(822/LAM9)   23424423222226143333322     Unk-259         r            s   s   s
  5     2011                M     27    Marrakech     Pulmonary           ▪▪▪▪▪▪▪▪▫▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   NC(1708/LAM9)         224244322324226173347322    271--62         s            s   s   s
  7     2011                M     55    Rabat         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▫▪   NC(1074/LAM9)         244254331324224163333422    Unk-578         s            s   s   s
  13    2011                M     60    Rabat         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▫▫▫▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   NC(273/LAM9)          244244322123225192346522    Unk- 488        s            s   s   s
  15    2011                F     29    Rabat         Extrapulmonary      ▪▪▪▪▪▪▪▪▪▪▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   NC(252/LAM9)          242244322324226163345522    Unk-62          s            s   s   s
  31    2011                M     42    Fes           Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   NC(731/LAM9)          244214322324226163332622    220--62         s            s   s   s
  167   2011                M     24    Fes           Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   NC(1071/LAM9)         224212332222126163334822    Unk-259         r            r   r   r
  2     2011                F     42    Marrakech     Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(53/T1)      224223422424225143333522    4464--15        s            s   s   s
  6     2010                M     52    Rabat         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(53/T1)      2421343222224445133346622   Unk-569         s            s   s   s
  22    2011                M     40    Fes           Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(53/T1)      223234332334425153333712    13387--15       s            s   s   s
  23    2011                F     31    Fes           Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(53/T1)      223234332334425153333712    13387--15       s            s   s   s
  42    2011                M     27    Sale          Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(53/T1)      2141251322344225113333832   682--15         s            s   s   s
  51    2011                F     36    Oujda         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(53/T1)      2432443323344251533431032   Unk-15          s            s   s   s
  34    2011                M     32    Rabat         Extrapulmonary      ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(53/T1)      224243322334225153343222    7048--15        s            s   s   s
  71    2011                F     42    Sale          Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster F(53/T1)      212224131232425113333122    Unk-116         s            s   s   s
  9     2011                M     33    Rabat         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▫▫▫▫▫▫▫▫▪▪▪▪▪▪▪   NC(602/T1)            223235372532423123333732    Unk-31          r            s   s   s
  14    2011                M     33    Rabat         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▪▪▪▫▫▫▫▪▪▪▪▪▪▪   NC(462/T1)            263244442634425153333612    Unk-15          s            s   s   s
  25    2011                M     60    Rabat         Pulmonary           ▪▪▪▪▪▪▪▪▫▫▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▫▪▪▪   NC(784/T2)            244244322124225192346522    Unk-85          s            s   s   s
  73    2011                F     24    Sale          Pulmonary           ▪▪▪▪▫▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▪▪▫▪▫▫▫▫▪▪▪▪▪▪▪   NC(443/Clade U)       223234331234425153333732    296--26         r            s   s   s
  81    2011                F     18    Sale          Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▫▪▪▪▪▪▪   NC(1070/Clade U)      134254332224126161332632    Unk-349         s            s   s   s
  61    2011                M     28    Rabat         Pulmonary           ▫▫▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▫▫▪▫▫▫▫▪▪▪▪▪▪▪   Unk                   223235332432423153333232    2786--31        s            s   s   s
  78    2011                F     24    Sale          Pulmonary           ▪▪▪▪▪▪▪▫▫▫▫▫▫▪▪▪▪▪▪▪▫▫▫▫▫▫▫▪▪▪▪▪▫▫▫▫▪▪▪▫▫▫▫   Unk                   134264332224126133332832    2613--159       s            s   s   s
  89    2012                F     18    Tanger        Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫   Unk                   134264332224126133332832    446--51         s            s   s   s

ID: Identifying number

DST: Drug SusceptibilityTesting

MLVA-MtbC15-9: Multi Locus Variant Allele-Mycobacterium tuberculosis complex15-9

Molecular cluster analysis {#sec016}
--------------------------

A subset of MTBC isolates (75/168) was subjected to 24-locus MIRU-VNTR typing. These isolates were selected to cover the different cities included in the study and different already established spoligotype families; they were originated from both pulmonary and extrapulmonary TB patients, with different drug susceptibility profiles (pansusceptible, polyresistant and MDR) ([Table 2](#pone.0135695.t002){ref-type="table"}). Among the 75 isolates, molecular cluster analysis based on 24-locus MIRU-VNTR genotypes identified 69 distinct genotypes, only including 5 clusters comprising from 2 (n = 4) to 3 isolates (n = 1) each (total of 11 isolates) and 64 unique types ([Fig 1](#pone.0135695.g001){ref-type="fig"} and [Table 2](#pone.0135695.t002){ref-type="table"}).

![Genetic tree based on spoligotyping and 24-locus MIRU-VNTR data of 75 *M*. *tuberculosis* isolates from10 Moroccan cities.\
A dendogram was generated using the UPGMA algorithm using tools available from the MIRU-VNTR*plus* identification database (see text). Isolates are identified according to their corresponding spoligotype international type (SIT; boxed), according to the SITVIT database.](pone.0135695.g001){#pone.0135695.g001}

Out of these unique types, 5 could not be assigned into well-determined genotypic lineage in the MIRU-VNTR*plus* database, SpolDB4 and SITVIT database and as such were labeled as "unknown". Importantly, the largest spoligotyping defined clusters were very efficiently subdivided by MIRUs, as e.g spoligotyping cluster ST42 (LAM), which formed a block of 29 isolates, was almost completely resolved, with only four remaining clustered isolates. Likewise, the second largest spoligotyping defined cluster ST50 (Haarlem) was also almost completely resolved, with only a single cluster of 2 isolates remaining. Thus, among the 75 isolates, the MIRU- based clustering rate corresponded 14.66% versus 76% for spoligotyping. The isolates within the five 24-locus MIRU-VNTR-based clusters showed identical spoligotype profiles, except in two cases, including a generic ST53/T1 and a ST42/LAM9 spoligotypes, and perhaps more unexpectedly, a ST50/Haarlem and a ST42/LAM9 spoligotypes, respectively.

When analyzed at the scale of the full isolate subset, groupings based on 24-locus MIRU-VNTR and spoligotyping results were fairly congruent ([Fig 1](#pone.0135695.g001){ref-type="fig"} and [Table 3](#pone.0135695.t003){ref-type="table"}). Two main strain groups were identified on the basis of the MIRU-VNTR-based tree, essentially composed of isolates with Haarlem spoligotypes (and isolates with generic T spoligotypes), and LAM spoligotypes (also with isolates with generic T spoligotypes), respectively. A few outliers with apparently discordant grouping were detected in either part of the tree, e.g., two ST42/LAM9 isolates (including one clustered with a T1 isolate) found among otherwise Haarlem branches.

10.1371/journal.pone.0135695.t003

###### Detailed Results obtained including demoraphic, drug-resistance and genotyping information on 5 clusters including 11 isolates defined by 24-loci MIRU patterns from 75 *M*.*tuberculosis* strain isolated in Morocco.

![](pone.0135695.t003){#pone.0135695.t003g}

  ID    Year of Isolation   Sex   Age   City         Site of Infection   Spoligotype Description                       Cluster(SIT/Clade)     MIRU24 profil               Cluster/MLVA MtbC15-9
  ----- ------------------- ----- ----- ------------ ------------------- --------------------------------------------- ---------------------- --------------------------- -----------------------
  17    2011                M     19    Rabat        Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▪▫▫▫▫▪▪▪▪▪▪▪   Cluster A(50/H3)       233235322634425154233432    Cluster A1(9927--415)
  79    2012                M     31    Rabat        Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▪▫▫▫▫▪▪▪▪▪▪▪   Cluster A(50/H3)       233235322634425154233432    Cluster A1(9927--415)
  26    2011                M     20    Sale         Extrapulmonary      ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   NC (ST42/LAM9)         134243352324126153332932    Cluster B1(358--51)
  16    2011                M     31    Rabat        Extrapulmonary      ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▪▫▫▫▫▪▪▪▪▪▪▪   NC (ST50/H3)           1342243352324126153332932   Cluster B1(358--51)
  51    2011                F     36    Oujda        Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   NC (ST53/T1)           2432443323344251533431032   Cluster C1(Unk-15)
  58    2011                M     24    Sale         Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   NC (ST42/LAM9)         2432443323344251533431032   
  166   2012                F     26    Meknes       Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster B(ST42/LAM9)   244244321322225172346522    ClusterD1(10248-Unk)
  168   2012                F     20    Meknes       Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster B(ST42/LAM9)   244244321322225172346522    ClusterD1(10248-Unk)
  169   2012                M     19    Sidi Kacem   Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster B(ST42/LAM9)   244244321322225172346522    ClusterD1(10248-Unk)
  22    2011                M     40    Fes          Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster C(ST53/T1)     223234332334425153333712    Cluster E1(13387--15)
  23    2011                F     31    Fes          Pulmonary           ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▫▫▫▫▪▪▪▪▪▪▪   Cluster C(ST53/T1)     223234332334425153333712    Cluster E1(13387--15)

ID: Identifying number

MLVA-MtbC15-9: Multi Locus Variant Allele-Mycobacterium tuberculosis complex15-9

Regarding the allelic diversity of the MIRU-VNTR loci, the discriminatory power was calculated using HGDI (summarized in [Table 4](#pone.0135695.t004){ref-type="table"}). The allelic diversity of the loci was classified as very discriminant \[Hunter-Gaston Index (HGI)\>0.6\], moderately discriminant (0.3\<HGI\<0.6) and poorly discriminant (HGI\<0.3) \[[@pone.0135695.ref033]\]. Among the 24-loci, we note that loci MIRU 4052, 802, 2996, 2163b, 3690, 1955, 424, 2531, 2401 and 960 were highly discriminative (HGDI\>0.6) whereas loci MIRU 577, 4156, 2165, 2347, 3192 and 154 were moderately discriminative (0.6\<HGDI\<0.3) and loci MIRU 2059, 3007, 1644, 580, 3171, 2461, 4348, 2687 were poorly discriminative (HGDI\<0.3).

10.1371/journal.pone.0135695.t004

###### Allelic polymorphism of 24 mycobacterial interspersed repetitive units (MIRUs) loci from 75 MTB isolates from patients with tuberculosis in different regions of Morocco

![](pone.0135695.t004){#pone.0135695.t004g}

  MIRU- VNTR Locus   Allele number   Allelic diversity (h)   Conclusion                                                         
  ------------------ --------------- ----------------------- ------------ ---- ---- ---- ---- ---- ---- --- --- --- --- ------- -------------------------
  **154**                                                    18           57                                            0.36    Moderately discriminant
  **424**                                                    3            31   17   23        1                         0.68    Very discriminant
  **577**                                                                 6    27   40   2                              0.57    Moderately discriminant
  **580**                            1                       3            70   1                                        0.12    Poorly discriminant
  **802**            1                                       9            9    23   24   4    3    1    1               0.77    Very discriminant
  **960**                                                                 5    10   42   16   2                         0.61    Very discriminant
  **1644**                                                   2            6    65   2                                   0.23    Poorly discriminant
  **1955**                                                   1            28   29   1    5    1    10                   0.68    Very discriminant
  **2059**                                                   14           61                                            0.29    Moderately discriminant
  **2163b**                                                  2            19   33   9    4    7         1               0.71    Very discriminant
  **2165**                                                                41   31   3                                   0.52    Moderately discriminant
  **2347**                                                                25   1    49                                  0.45    Moderately discriminant
  **2401**                                                   17           27        31                                  0.64    Very discriminant
  **2461**                                                   1            72        2                                   0.07    Poorly discriminant
  **2531**                                                                2    10   4    33   25   1                    0.67    Very discriminant
  **2687**                                                   75                                                         -0.01   Poorly discriminant
  **2996**                                                   2            4    8    7    32   10   8    2   2           0.76    Very discriminant
  **3007**                                                   1            8    62   4                                   0.27    Moderately discriminant
  **3171**                                                   1            3    71                                       0.09    Poorly discriminant
  **3192**                                                                1    52   21   1                              0.43    Moderately discriminant
  **3690**                                                   1            19   35   4    7    7    1                1   0.69    Very discriminant
  **4052**           1                                       4            7    4    5    15   13   16   5   2   3       0.86    Very discriminant
  **4156**                                                   3            37   35                                       0.53    Moderately discriminant
  **4348**                                                                74   1                                        0.01    Poorly discriminant

Discussion {#sec017}
==========

This is the first study to explore the usefulness of standard 24-locus based MIRU-VNTR typing for molecular epidemiological study of MTBC strains from Morocco. Hitherto, MTBC population structure and tuberculosis transmission were only studied at the national level by using spoligotyping alone or in conjunction with 12-loci MIRUs \[[@pone.0135695.ref016],[@pone.0135695.ref017]\]. In comparison to these two typing methods, the discriminatory power of 24-locus MIRU-VNTR typing has been shown to be higher in a number of other settings in Europe and elsewhere \[[@pone.0135695.ref004],[@pone.0135695.ref034],[@pone.0135695.ref035]\], and often similar to that of IS*6110*-based RFLP when comparison with the latter method were made \[[@pone.0135695.ref006]--[@pone.0135695.ref009]\].

In order to explore the informative value of 24-locus MIRU-VNTR typing, we selected 75 representatives from a baseline sample of 168 MTBC isolates screened by spoligotyping from 10 cities with high burden of TB, for which we also determined the drug resistance profiles. As summarized in [Table 2](#pone.0135695.t002){ref-type="table"}, 24-locus based MIRU-VNTR typing largely reduced the clustering defined by spoligotyping alone or even by spoligotyping combined with 12-locus MIRU-VNTR typing, from 76% and 48% to 14.6%, respectively. It is noteworthy that this effect was particularly noticed for large clusters initially defined by spoligotypes such as ST42 (LAM) and ST50 (Haarlerm), which are predominant in Morocco, as seen in this study as well in previous reports \[[@pone.0135695.ref016],[@pone.0135695.ref017]\]. After analysis with 24 loci, these initial spoligotype-based clusters were reduced to a few clusters of at most three isolates. Hence, no correlation was apparent between particular MIRU-VNTR types and drug resistance profile, except for three MDR isolates that were confirmed to be part of a same familial outbreak (see just below). Contact tracing could not be conducted for all these remaining clustered isolates in order to confirm TB transmission assumed from molecular clustering. It is noteworthy however that the single cluster of three isolates corresponded to two previously treated MDR-TB cases and one new MDR-TB case known to be contact a same index case and belonging to a same family, albeit residing in 3 different administrative regions (Fes-Boulmane, Meknes-Tafilalet and Garb-Chrarda-BniHssen) during 2011. The consistent clustering of these three cases lends some degree of confidence to the overall reliability of the molecular results obtained. This is also suggested by the overall degree of congruence observed between groupings on the basis on the 24-locus MIRU-VNTR-based tree and grouping of the corresponding spoligotypes. Only a few outliers were detected, for which samples were unavailable for repeat experiments in order to see if these few discordant groupings reflected some homoplasy linked to spoligotyping or MIRU-VNTR data \[[@pone.0135695.ref036]\], or technical errors. In this sample collection, two different isolates were also obtained from one patient with both pulmonary and extrapulmonary TB. Both spoligotyping and 24-locus MIRU-VNTR typing showed that the strain isolated from sputum defined as ST273/LAM9 and MLVA MTBC Unk-488 differed from the one isolated from pleural liquid clinical sample, defined as ST784/T2 and MLVA MTBC Unk-85. This concordant result obtained by independent typing methods suggests a case of mixed infection with compartmentalization of different strains in distinct body sites \[[@pone.0135695.ref037]\]. Considering the full set of spoligotyping data obtained for the 168 study isolates, our results confirm that MTBC isolates in our country are essentially limited to evolutionary modern principle genetic group (PGG)2/3 strains (namely LAM, Haarlem, and T), as found in previous reports and different patient populations \[[@pone.0135695.ref016],[@pone.0135695.ref017]\]. Overall, when our results are compared with those of these previous reports, it seems that MTBC population structure in Morocco is highly stable, with almost same spoligotype distributions from 2002 to 2012, and highly homogeneous. Strikingly, each of the 3 predominant LAM, Haarlem and T families was characterized by one or two predominant SITs (i.e.SIT42 for LAM, SIT50 for Haarlem and SIT53 for T), almost always representing the prototype of each spoligotype family with large geographical distribution described in different databases \[[@pone.0135695.ref021],[@pone.0135695.ref022]\]. It can be speculated that this predominance of a few SITs, especially that of LAM family, reflects some founder effect linked to the introduction of the corresponding MTBC clonal branches in the region. In contrast, although we found a total of 49 profiles identified among the 168 isolates, we did not find spoligotypes with strong local phylogeographical specificity ([Table 2](#pone.0135695.t002){ref-type="table"}). We only identified 5 Beijing isolates from three different cities (Marrakech, Rabat and Casablanca), while a previous study also detected a few isolates with such genotype in Marrakech, Fes and Sale \[[@pone.0135695.ref016]\]. This low prevalence of Beijing strains in Morocco plausibly reflects the low level of human immigration from East Asia, where this strain lineage largely prevails and probably originally emerged according to recent analyses \[[@pone.0135695.ref011]\]. MTBC isolates with a Beijing genotype are often, albeit not always associated with MDR-TB, especially Eurasia and East-Asian countries \[[@pone.0135695.ref011],[@pone.0135695.ref038]--[@pone.0135695.ref041]\]. In our study, a single Beijing isolate obtained from an extrapulmonary TB patient in Casablanca, was MDR while the 4 other isolates were pansusceptible. This is in accordance with previous studies, suggesting little to no association of Beijing genotypes with MDR-TB in the country \[[@pone.0135695.ref012],[@pone.0135695.ref016]\]. However, more vigorous investigations are needed to further study this question and to trace the possible origins of the Beijing isolates identified in our and previous studies \[[@pone.0135695.ref016]\]. We also detected 4 isolates with another, more geographically specific spoligotype, belonging to the SIT61/CAM spoligotype family in 3 cities: Fes (n = 1), Marrakech (n = 1) and Rabat (n = 2). As this spoligotype has strong phylogeographical specificity to Cameroon and its neighboring countries in West Africa \[[@pone.0135695.ref021],[@pone.0135695.ref022],[@pone.0135695.ref042]\], the presence of these strains in Morocco is suggestive of importation by sub-Saharan migrants to and across Morocco \[[@pone.0135695.ref043]--[@pone.0135695.ref045]\]. Finally, we detected two isolates of T2 spoligotype family, and one with a SIT443/U pattern, none of which were previously described in Morocco. Such patterns have been essentially reported from different region of Asia and Canada \[[@pone.0135695.ref021]\], and Asia USA and Europe, respectively \[[@pone.0135695.ref021]\].

Also in line with finding from other, previously studied Moroccan patient population \[[@pone.0135695.ref016],[@pone.0135695.ref017]\], we observed very little evidence of multidrug resistance with a frequency of only 3.0% among the new cases in this study. Among the remaining cases, 85.7% were pansusceptible, and the remaining 10.1% showed resistance to one or more drugs.

In conclusion, although this study was limited by a relatively small sample size, the obtained results support the use of 24-locus MIRU-VNTR typing in our country, for substantially reducing the degree of over estimation of epidemiological links inferred among isolates analyzed by spoligotyping alone or in combination with 12-locus MIRU-VNTR typing. This use should be especially beneficial to distinguish the many strains that apparently share a few highly predominant prototypic spoligotypes. We therefore hope that its implementation will help enhanced TB control program in Morocco to reduce the TB burden in the country \[[@pone.0135695.ref004],[@pone.0135695.ref030],[@pone.0135695.ref036]\]. As a future cost-effective strategy and when possible, whole genome sequencing (WGS) could then be specifically applied on the remaining MIRU-VNTR-based clusters to further test their possible significance in terms of ongoing TB transmission, given the superior resolution power provided by WGS to resolve TB outbreaks \[[@pone.0135695.ref046],[@pone.0135695.ref047]\].
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